COVID-19 vaccine-associated anaphylaxis: Astatement of the World Allergy OrganizationAnaphylaxis Committee (2021).
Polyethylene glycol-induced systemic allergic reactions (anaphylaxis) (2020).
Anti-PEG IgE In anaphylaxis associated with Polyethylene Glycol (2020).
Maintaining Safety with SARS-CoV-2 Vaccines (2020).
Allergic reactions to the first COVID-19 vaccine: a potential role of Polyethylene glycol? (2020).
A thermostable mRNA vaccine against COVID-19 (2020).
Polyethylene Glycol Is a Cause of IgE-Mediated anaphylaxis (2019).
Immediate hypersensitivity to polyethylene glycols in unrelated products: when standardization in the nomenclature of the components of drugs, cosmetics, and food becomes necessary (2019).
Hypersensitivity to Polyethylene Glycols & Polysorbates (2019).
Immediate Hypersensitivity to Polyethylene Glycols and Polysorbates: More Common Than We Have Recognized (2019).
Optimization of a PEGylated glucuronide monomethylauristatin E Linker for Antibody–Drug Conjugates (2017).
Analysis of pre-existing IgG and IgM antibodies against Polyethylene
Glycol (PEG) in the general population (2016).
Allergic reactions associated with pegaspargase in adults (2016).
Immediate-type hypersensitivity to polyethylene glycols: a review (2016).
Polyethylene glycol as a cause of anaphylaxis (2016).
Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer (2016).
Anaphylaxis following a transvaginal ultrasound (2016).
PEGylation of biopharmaceuticals: A review of chemistry and nonclinical safety information of approved drugs (2016).
Anaphylaxis to Polyethylene Glycol (Colyte®) in a patient with
Anti-PEG antibodies in the clinic: current issues and beyond
Allergic reaction to polyethylene glycol in a painter (2015).
Anaphylactic shock caused by ingestion of Polyethylene Glycol (2015).
Pre-existing anti–polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer (2015).
Urticaria due to polyethylene glycol-3350 and electrolytes for oral solution in a patient with jejunal nodular lymphoid hyperplasia (2015).
Polyethylene Glycols (PEG) and related structures: overlooked allergens in the perioperative setting (2015).
Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients (2014).
Potential induction of anti-PEG antibodies and complement activation
toward PEGylated therapeutics (2014).
Discussion about Several Potential Drawbacks of PEGylated Therapeutic Proteins (2014).
A phase II clinical trial of polyethylene glycol-conjugated L-asparaginase in patients with advanced ovarian cancer: Early closure for safety (2013).
PEGylation of Biologics (2013)
A case of anaphylaxis caused by macrogol 3350 after injection of a corticosteroid (2012).
Positive skin test to pegylated drug in a patient with anaphylaxis to
polyethylene glycol (2012).
Pegylated interferon, but not conventional interferon therapy, induced severe skin lesions (2012).
Immunogenicity of Polyethylene Glycol (PEG) (review, 2011).
A rare case of anaphylaxis to bowel Prep: A case report and review of the literature (2011).
Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives (2010).
PEGylated protein drugs: basic science and clinical applications (Book, 2009).
Immediate allergic reactions by polyethylene glycol 4000: two cases (2008).
Poly(ethylene glycol)s generate complement activation products in human
serum through increased alternative pathway turnover and a MASP-2-dependent process (2008).
Anaphylactic shock after oral intake and contact urticaria due to polyethylene glycols (2007).
Antibody against Poly(Ethylene Glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients (2007).
Fatal aspiration of polyethylene glycol solution (2006).
Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes (2006).
Two cases of anaphylaxis to macrogol 6000 after ingestion of drug tablets (2006).
Anaphylactic shock: pathophysiology, recognition, and treatment (2004).
Role of complement activation in hypersensitivity reactions to doxil and hynic PEG liposomes: experimental and clinical studies (2002)
Urticarial reaction to oral polyethylene glycol electrolyte lavage solution (1992)
Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors (1984)
Anaphylaxis to polyethylene glycol (PEG) in a multivitamin tablet (1982)